专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012083005A3 MICRORNA INHIBITORS COMPRISING LOCKED NUCLEOTIDES 审中-公开
标题翻译：包含锁定核苷酸的微核糖核酸抑制剂
公开(公告)号：WO2012083005A3
公开(公告)日：2012-08-16
申请号：PCT/US2011065121
申请日：2011-12-15
申请人： MIRAGEN THERAPEUTICS , DALBY CHRISTINA , MARSHALL WILLIAM S , ROOIJ EVA VAN , MONTGOMERY RUSTY
发明人： DALBY CHRISTINA , MARSHALL WILLIAM S , ROOIJ EVA VAN , MONTGOMERY RUSTY
IPC分类号： C12Q1/68
CPC分类号： C12N15/113 , A61K31/7105 , C12N2310/113 , C12N2310/315 , C12N2310/3231 , C12N2310/346 , C12Q2600/178
摘要： The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-208 family miRNAs, including miR-208a, miR-208b, and/or miR-499. The invention provides in some embodiments, oligonucleotides capable of inhibiting, in a specific fashion, the expression or abundance of each of miR-208a, miR-208b, and miR-499. The invention further provides pharmaceutical compositions comprising the oligonucleotides, and methods of treating patients having conditions or disorders relating to or involving a miR-208 family miRNA, such as a cardiovascular condition. In various embodiments, the oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability.
摘要翻译：本发明提供了能够抑制miR-208家族miRNA（包括miR-208a，miR-208b和/或miR-499）的表达（例如丰度）的化学修饰的寡核苷酸。本发明在一些实施方案中提供了能够以特定方式抑制miR-208a，miR-208b和miR-499中的每一种的表达或丰度的寡核苷酸。本发明进一步提供了包含寡核苷酸的药物组合物，以及治疗患有与miR-208家族miRNA相关或涉及miR-208家族miRNA（例如心血管病症）的病症或病症的患者的方法。在不同的实施方案中，寡核苷酸在效力，递送效率，靶标特异性，毒性和/或稳定性中的一种或多种方面提供优势。

2. 发明申请

WO2016197024A3 MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL) 审中-公开
标题翻译： MIR-155用于治疗胰岛细胞淋巴瘤（CTCL）的抑制剂
公开(公告)号：WO2016197024A3
公开(公告)日：2017-02-09
申请号：PCT/US2016035865
申请日：2016-06-03
申请人： MIRAGEN THERAPEUTICS INC
发明人： RODMAN DAVID , SETO ANITA , DALBY CHRISTINA , JACKSON AIMEE , BEATTY XUAN
IPC分类号： C12N15/113 , A61K31/7088 , A61P35/00
CPC分类号： C12N15/113 , C12N2310/113 , C12N2310/315 , C12N2310/3231 , C12N2310/344 , C12N2310/322 , C12N2310/3531
摘要： The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR- 155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
摘要翻译：本发明提供miR-155的寡核苷酸抑制剂及其组合物。本发明还提供了通过向受试者施用miR-155的寡核苷酸抑制剂来治疗受试者的癌症如T细胞淋巴瘤的方法。本发明还提供了通过施用寡核苷酸抑制剂来减少或抑制恶性T细胞增殖的方法的miR-155。

3. 发明申请

WO2016022536A3 INHIBITORS OF MYH7B AND USES THEREOF 审中-公开
标题翻译： MYH7B的抑制剂及其用途
公开(公告)号：WO2016022536A3
公开(公告)日：2016-03-31
申请号：PCT/US2015043571
申请日：2015-08-04
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY , DALBY CHRISTINA
IPC分类号： A61K48/00 , C07H21/04
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , A61K2300/00 , C12N2310/3521
摘要： The present invention provides nucleic acid inhibitors of MYH7B and compositions thereof. The present invention also provides methods of treating or preventing a cardiac disorder such as cardiac hypertrophy, myocardial infarction, or heart failure in a subject by administering to the subject an inhibitor of MYH7B. The present invention further provides methods of modulating the activity or expression of ?-MHC in cardiac cells of a subject by administering to the subject an inhibitor of MYH7B.
摘要翻译：本发明提供了MYH7B的核酸抑制剂及其组合物。本发明还提供了通过向受试者施用MYH7B抑制剂来治疗或预防受试者的心脏病，例如心脏肥大，心肌梗塞或心力衰竭的方法。本发明进一步提供了通过向受试者施用MYH7B抑制剂来调节受试者心脏细胞中α-MHC活性或表达的方法。

4. 发明公开

EP3201213A4 MIR-29 MIMICS AND USES THEREOF 无效转让
公开(公告)号：EP3201213A4
公开(公告)日：2018-07-25
申请号：EP15840320
申请日：2015-09-08
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY L , DALBY CHRISTINA , VAN ROOIJ EVA , GALLANT-BEHM CORRIE
IPC分类号： C07H21/02
CPC分类号： C12N15/113 , A61K9/0073 , A61K9/0075 , A61K9/0078 , A61K31/7105 , A61K31/713 , C12N2310/113 , C12N2310/141 , C12N2310/315 , C12N2310/3231 , C12N2310/343 , C12N2310/346 , C12N2320/51 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533
摘要： The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.

5. 发明公开

EP2863956A4 INHIBITORS OF THE MIR-15 FAMILY OF MICRO-RNAS 审中-公开
标题翻译： INHIBITOREN DER MIR-15-FAMILIE VON MICR-RNS
公开(公告)号：EP2863956A4
公开(公告)日：2016-01-20
申请号：EP13806131
申请日：2013-06-21
申请人： MIRAGEN THERAPEUTICS INC
发明人： VAN ROOIJ EVA , DALBY CHRISTINA , SETO ANITA
IPC分类号： A61K48/00 , C07H21/04 , C12N15/11
CPC分类号： C12N15/113 , C12N2310/113 , C12N2310/315 , C12N2310/3231 , C12N2310/344 , C12N2310/346

6. 发明公开

EP2635681A4 BASE MODIFIED OLIGONUCLEOTIDES 有权
标题翻译： OLIGONUKLEOTIDE MIT改良剂基础
公开(公告)号：EP2635681A4
公开(公告)日：2015-01-14
申请号：EP11838938
申请日：2011-11-07
申请人： MIRAGEN THERAPEUTICS
发明人： VAGLE KURT , DALBY CHRISTINA , MARSHALL WILLIAM S
IPC分类号： C12N15/11
CPC分类号： C12N15/113 , C12N15/111 , C12N2310/141 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/33 , C12N2310/3521 , C12N2310/3523 , C12N2310/3525 , C12N2310/3527 , C12N2310/3529 , C12N2320/52

7. 发明公开

EP3177327A4 INHIBITORS OF MYH7B AND USES THEREOF 审中-公开
公开(公告)号：EP3177327A4
公开(公告)日：2018-03-14
申请号：EP15829559
申请日：2015-08-04
申请人： MIRAGEN THERAPEUTICS INC
发明人： MONTGOMERY RUSTY , DALBY CHRISTINA
IPC分类号： C12N15/113 , A61K31/712
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/713 , A61K45/06 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , A61K2300/00 , C12N2310/3521
摘要： The present invention provides nucleic acid inhibitors of MYH7B and compositions thereof. The present invention also provides methods of treating or preventing a cardiac disorder such as cardiac hypertrophy, myocardial infarction, or heart failure in a subject by administering to the subject an inhibitor of MYH7B. The present invention further provides methods of modulating the activity or expression of β-MHC in cardiac cells of a subject by administering to the subject an inhibitor of MYH7B.

8. 发明专利

DK3354734T3 OLIGONUKLEOTID-BASEREDE HÆMMERE OMFATTENDE LÅST NUKLEINSYREMØNSTER 未知
公开(公告)号：DK3354734T3
公开(公告)日：2020-06-29
申请号：DK18154472
申请日：2013-06-21
申请人： MIRAGEN THERAPEUTICS INC
发明人： VAN ROOIJ EVA , DALBY CHRISTINA , MONTGOMERY RUSTY
IPC分类号： C12N15/113 , A61K31/712

9. 发明专利

RU2718534C2 ИНГИБИТОРЫ MIR-155 ДЛЯ ЛЕЧЕНИЯ КОЖНОЙ T-КЛЕТОЧНОЙ ЛИМФОМЫ (CTCL) 未知
公开(公告)号：RU2718534C2
公开(公告)日：2020-04-08
申请号：RU2017146374
申请日：2016-06-03
申请人： MIRAGEN THERAPEUTICS INC
发明人： RODMAN DAVID , SETO ANITA , DALBY CHRISTINA , JACKSON AIMEE , BEATTY XUAN
IPC分类号： C12N15/113 , A61P35/00
摘要： Изобретениеотноситсяк биотехнологии. Описанолигонуклеотидныйингибитор miR-155, содержащий/состоящийизпоследовательность/и 5’-lCs.dAs.lCs.dGs.dAs.lTs.lTs.dAs.lGs.dCs.lAs.lTs.lTs.lA-3’ (SEQ ID NO: 25), где l представляетсобойзамкнутыйнуклеотид; d представляетсобойдезоксирибонуклеотид; s представляетсобойфосфортиоатнуюсвязьилиолигонуклеотидныйингибитор miR-155, содержащий/состоящийизпоследовательность/и 5’-lCs.dAs.lCs.dGs.dAs.lTs.lTs.dAs.lGs.lCs.dAs.lTs.lTs.lA-3’ (SEQ ID NO: 53), где l представляетсобойзамкнутыйнуклеотид; d представляетсобойдезоксирибонуклеотид; s представляетсобойфосфортиоатнуюсвязь. Изобретениеможетбытьиспользованодлялечениязлокачественнойопухоли, такойкак T-клеточнаялимфома. Изобретениетакжеможетбытьиспользованодлясниженияилиингибированияпролиферацииозлокачествленных T-клеток. 7 н. и 27 з.п. ф-лы, 28 ил., 14 табл., 13 пр.

10. 发明专利

AU2016270434A1 miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) 未知
公开(公告)号：AU2016270434A1
公开(公告)日：2017-12-07
申请号：AU2016270434
申请日：2016-06-03
申请人： MIRAGEN THERAPEUTICS INC
发明人： RODMAN DAVID , SETO ANITA , DALBY CHRISTINA , JACKSON AIMEE , BEATTY XUAN
IPC分类号： C12N15/113 , A61K31/7088 , A61P35/00
摘要： The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR- 155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式